Spain's Fernando Verdasco has accepted a two-month provisional suspension for an "inadvertent" positive test ©Getty Images

Spain's Fernando Verdasco has accepted a two-month provisional suspension for the "inadvertent" presence of the ADHD medication, methylphenidate, in a urine sample, the International Tennis Integrity Agency (ITIA) has confirmed. 

Verdasco, 38, who reached the Australian Open semi-finals in 2009 and US Open quarter-finals in 2009 and 2010, was tested at an Association of Tennis Professionals Challenger event in Rio de Janeiro in February 2022.

He admitted the rules breech and claimed that he had been medically diagnosed with attention deficit hyperactivity disorder (ADHD) since he was four and legitimately used methylphenidate as medication prescribed by his physician to treat the condition in accordance with a therapeutic use exemption (TUE) but had forgotten to renew his TUE when it expired.

Since the finding, there has been an ongoing TUE re-application process involving the player, the World Anti-Doping Agency (WADA) and the ITIA.

The player has been granted a new TUE by WADA for his medication and has withdrawn from the retroactive TUE process to resolve this case.

The ITIA said it accepts that the player did not intend to cheat, that his violation was inadvertent and unintentional, and that he bears "No Significant Fault or Negligence" for it.

In the specific circumstances of this case, based on the player's degree of fault, tennis' anti-doping rules allow for the applicable period of ineligibility to be reduced from two years to two months.

The player voluntarily accepted a provisional suspension after being notified of the charge.

The two-month period of ineligibility commenced on the date of the player’s voluntary provisional suspension and will conclude on January 8 2023.